MedTrace Logo

Safety and Efficacy of Umbilical Cord Blood Regulatory T Cells Plus Liraglutide on Autoimmune Diabetes

NCT03011021 · Status: UNKNOWN · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 40

Last updated 2023-03-14

No results posted yet for this study

Summary

The purpose of this study is to investigate the safety and therapeutic effect of ex-vivo expanded umbilical cord blood regulatory T cells adjunct with Liraglutide on autoimmune diabetes.

Conditions

  • Type1 Diabetes Mellitus
  • Autoimmune Diabetes

Interventions

DRUG

Liraglutide

Dose escalation of Liraglutide starts from 0.6 mg up to 1.2 mg per day.

BIOLOGICAL

UCB-Treg

Receive Treg infusion: 1\~5\*10\^6/kg b.w. in 100ml normal saline

DRUG

Insulin

Receive insulin following clinician's instruction.

Sponsors & Collaborators

  • Second Xiangya Hospital of Central South University

    lead OTHER

Principal Investigators

  • Zhiguang Zhou, MD/PhD · Second Xiangya Hospital

  • Haibo Yu, MD/PhD · Second Xiangya Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-01-31
Primary Completion
2025-06-30
Completion
2025-06-30

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03011021 on ClinicalTrials.gov